The downgrade by UBS from Buy to Neutral suggests a less optimistic view on CVS Health's future stock performance, potentially due to underlying challenges or market conditions. The significant reduction in the price target from $85 to $60 further underscores a cautious or bearish outlook, which could influence investor sentiment and lead to a short-term decrease in stock price.